Monday, 07 October 2024
A cross-disciplinary team, led by the University of Glasgow, alongside the Universities of Nottingham and Strathclyde, will use pioneering technology to manufacture human stem cells outside the body, in the hope these cells could help tissue regeneration to repair broken bones, help with transplant therapies and help to develop new approaches to blood cancer treatment.
The new project is made possible with £11m, awarded by the UKRI Engineering and Physical Sciences Research Council (EPSRC), as part of funding for five new research hubs aimed at tackling some of the biggest problems in healthcare and society with ground-breaking new technologies and approaches.
Led by Professor Matthew Dalby from the University of Glasgow’s School of Molecular Biosciences, the MAINSTREAM project, which further benefits from £1.5m in partner (industry) contributions, will be a research and partnership hub for health technologies in manufacturing stem cells.
Mesenchymal stromal or stem cells (MSCs) are adult stem cells that can turn into bone, cartilage, ligament, tendon and fat-forming cells, with far-reaching potential, including tissue regeneration to repair broken bones.
These cells can also be used as a drug to prevent transplant rejection as they work to supress immune response, while their role in the development of blood cancers means they have potential to complement chemotherapy in regenerating healthy bone marrow and looking after healthy blood cells provided by bone marrow transplants.
Despite their massive potential in healthcare provision, and the fact that the first MSC-based clinical trial took place more than 25 years ago, MSC therapies are still not commonly used. This is due to the difficulty in growing these stem cells outside of the body, meaning only relatively few can be grown from each donor which keeps their price high and prevents production from being scaled up.
The MAINSTREAM project aims to address this problem through the development of new materials that MSCs can grow on in the laboratory (or, ultimately, in a factory) and can help them to retain their key stem cell characteristics, enabling them to be manufactured in large numbers. The research team will achieve this by developing novel materials that can mimic the areas of the human body these stem cells grow in naturally, to produce a large number of cells in the laboratory.
The team will then identify how to scale-up the technology, using approaches such as 3D printing, to allow future medicines to be manufactured affordably and sustainably. This will allow factory-based stem cell manufacture.
Professor Matthew Dalby said: “Stem cell manufacture can only successfully be achieved if we consider the development of materials that they can grow on and that ‘tell’ them what we want them to do at the same time that we consider how to manufacture the materials at scale. Otherwise, we would have the risk that we would make great materials that can’t be manufactured or manufacturable materials that just don’t work for the cells.
“The hub allows us to use the best of the national infrastructure to achieve this as well as work closely with industry, the NHS and, critically, with patients and the public. The team are fantastically fortunate to have the investment to make sure the UK is a leader in driving industry in this area.”
The project will seamlessly integrate innovate living materials capable of communicating with cells with advanced manufacturing techniques to enable the recreation of complex biological environments within scalable production processes.鈥�
EPSRC Executive Chair Professor Charlotte Deane said: “The five new hubs bring together a wealth of expertise from across academia, industry and charities to improve population health, transform disease prediction and diagnosis, and accelerate the development of new interventions.
“They represent an exciting range of adventurous techniques and approaches that have great potential to improving the lives of millions of people here in the UK and across the world.”
Story credits
More information is available from Faith Pring in the Press Office on faith.pring@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.